Market Access/ News/ News Alnylam gets NICE backing for porphyria therapy Givlaari Phil Taylor Alnylam, Givlaari, HEOR, NICE, porphyria, rare disease 0 Comment UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Share X Alnylam gets NICE backing for porphyria therapy Givlaari https://pharmaphorum.com/news/alnylam-gets-nice-backing-for-porphyria-therapy-givlaari/
Market Access/ News/ News/ News/ Patients Alnylam gets CHMP backing for second gene-silencing drug Givlaari Phil Taylor Alnylam, CHMP, gene silencing, Givlaari, rare disease, RNA interference 0 Comment Alnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP Share X Alnylam gets CHMP backing for second gene-silencing drug Givlaari https://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/
Alnylam, Givlaari, HEOR, NICE, porphyria, rare disease
0 Comment
